Invention Grant
- Patent Title: Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
-
Application No.: US14820323Application Date: 2015-08-06
-
Publication No.: US10285992B2Publication Date: 2019-05-14
- Inventor: Lawrence P. Wennogle , Peng Li
- Applicant: Intra-Cellular Therapies, Inc.
- Applicant Address: US NY New York
- Assignee: INTRA-CELLULAR THERAPIES, INC.
- Current Assignee: INTRA-CELLULAR THERAPIES, INC.
- Current Assignee Address: US NY New York
- Agency: Hoxie & Associates LLC
- Main IPC: A61K31/519
- IPC: A61K31/519 ; A61K31/197 ; A61K31/216 ; A61K45/06 ; A61K31/198 ; A61K31/341
Abstract:
The invention relates to the combination of inhibitors of phosphodiesterase 1 (PDE1) and inhibitors of Neprilysin (NEP) useful for the treatment of certain cardiovascular diseases or related disorders, e.g., hypertension, congestive heart disease, and post-myocardial infarction. In another embodiment, the invention relates to the combination of inhibitors of PDE1 and inhibitors of NEP for the treatment of diseases or disorders characterized by disruption of or damage to various cGMP/PKG mediated pathways in the cardiovascular system (e.g., in cardiac tissue or in arterial smooth muscle).
Public/Granted literature
- US20160038494A1 NOVEL COMBINATION Public/Granted day:2016-02-11
Information query
IPC分类:
